Mersana Therapeutics Inc., a Cambridge cancer therapeutics developer, has named board member Nicholas Bacopoulos as president and CEO. Julie Olson, who held the chief executive post, has been named chief technology officer, a newly created position.
Bacopoulos has served on the Mersana board since 2007. His 25 years of biotech and pharmaceutical experience includes a recent role as president and CEO of commercial HDAC inhibitor developer Aton Pharma Inc., which was bought by Merck & Co. Earlier positions include president and head of R&D at OSI Pharmaceuticals Inc. He worked for 18 years at Pzifer, serving as president and CEO of subsidiary Anaderm Research Corp. Bacopoulos earned a Ph.D. from the University of Iowa and a bachelor’s degree from Cornell College.